Amid growing concern over access to Covid-19 medical products, Moderna (MRNA) has decided not to enforce its patent rights related to its experimental vaccine and will also license its intellectual property to any Covid-19 vaccines to others after the pandemic has ended.
The decision means other companies or governments should not have concerns that the biotech would seek to prevent other Covid-19 vaccines from being developed based on its technology. “We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible,” the company said in a brief statement (here are the patents).
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
May one observe we should hope that – ““Every manufacturer of a vaccine, drug or diagnostic should follow suit … “
KEI has more commentary the Moderna statement here: https://www.keionline.org/34112